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OBJECTIVE — To evaluate the utility of GAD antibodies (GADAs) and islet antigen-2 anti-
bodies (IA-2As) in prediction of type 1 diabetes over 27 years in the general population and to
assess the 6-year rates of seroconversion.
RESEARCH DESIGN AND METHODS — A total of 3,475 nondiabetic subjects aged
3–18 years were sampled in 1980, and 2,375 subjects (68.3%) were resampled in 1986. All
subjectswereobservedfordevelopmentofdiabetestotheendof2007.GADAsandIA-2Aswere
analyzed in all samples obtained in 1980 and 1986.
RESULTS — A total of 34 individuals (1.0%; 9 developed diabetes) initially had GADAs and
22 (0.6%; 9 developed diabetes) IA-2As. Seven subjects (0.2%) tested positive for both autoan-
tibodies.Thepositiveseroconversionrateover6yearswas0.4%forGADAsand0.2%forIA-2As,
while the inverse seroconversion rates were 33 and 57%, respectively. Eighteen subjects (0.5%)
developed type 1 diabetes after a median pre-diabetic period of 8.6 years (range 0.9–20.3).
Initial positivity for GADAs and/or IA-2As had a sensitivity of 61% (95% CI 36–83) for type 1
diabetes. Combined positivity for GADAs and IA-2As had both a speciﬁcity and a positive
predictive value of 100% (95% CI 59–100).
CONCLUSIONS — One-time screening for GADAs and IA-2As in the general childhood
population in Finland would identify 60% of those individuals who will develop type 1
diabetes over the next 27 years, and those subjects who have both autoantibodies carry an
extremely high risk for diabetes. Both positive and inverse seroconversions do occur over time
reﬂecting a dynamic process of -cell autoimmunity.
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T
ype 1 diabetes is an immune-
mediated disease leading to chronic
insulin deﬁciency due to extensive
and selective -cell destruction in sub-
jects with increased genetic disease sus-
ceptibility (1). The clinical disease
manifestationrepresentsend-stageinsuli-
tis, since only 10–20% of the insulin-
producing -cells have been estimated to
still be functioning at the time of diagno-
sis(2).Theclinicaldiseasepresentationis
preceded by an asymptomatic period of
variable duration. -cell autoimmunity is
characterized by the presence of autoan-
tibodies, such as islet cell autoantibodies
(ICAs),insulinautoantibodies(IAAs),au-
toantibodies to the 65-kDa isoform of
GAD (GADAs), and autoantibodies to the
intracellular portion of the protein ty-
rosine phosphatase–related islet anti-
gen-2 molecule (IA-2As), in the
peripheral circulation (3). Many studies
(3–5) have shown that these antibodies
can be used efﬁciently for the prediction
of type 1 diabetes in ﬁrst-degree relatives
of affected patients. The combination of
GADAs and IA-2As has a high sensitivity
and speciﬁcity for type 1 diabetes in fam-
ily members, although prospective stud-
ies from birth have shown that IAAs are
usually the ﬁrst or among the ﬁrst anti-
bodies to appear in young children (6–
8). In a previous survey, we showed that
thepredictivecharacteristicsofcombined
positivity for GADAs and IA-2As were of
the same magnitude in the general popu-
lation as those seen among ﬁrst-degree
relatives over an observation period of 15
years (9). In this study, we set out to
assess the predictive characteristics of
GADAs and IA-2As over a period of 27
years in a population-based series of
3,475Finnishsubjectsinitiallyaged3–18
years. We also had the opportunity to de-
ﬁneinthispopulationtheratesofpositive
and inverse seroconversions over the ini-
tial 6 years of follow-up.
RESEARCH DESIGN AND
METHODS— A total of 3,596 chil-
dren and adolescents were initially re-
cruited in 1980 for a population-based
study on cardiovascular risk in young
Finns (10). Unselected Finnish subjects
aged 3, 6, 9, 12, 15, and 18 years at entry
of the study were recruited in ﬁve univer-
sity cities in Finland and in 12 rural com-
munities in their vicinity. Data on the
predictive value of GADAs and IA-2As in
the samples obtained in 1980 have been
reported earlier for a follow-period of 15
years (9). All subjects were invited for re-
examination in 1986. We tested all avail-
able samples of initially nondiabetic
subjects taken in 1980 (n  3,475; girls
50.7%) and 1986 (n  2,375; girls
52.8%) for GADAs and IA-2As. Subjects
who developed type 1 diabetes were
asked to report the diagnosis to their
study center. All subjects who developed
clinical diabetes by the end of year 2007
were identiﬁed from the Central Drug
Registry of the National Social Insurance
Institute as a secondary source. This reg-
istry has an ascertainment rate of 99%
for new patients with diabetes (11). The
diagnosis of type 1 diabetes required that
the patient was started on exogenous in-
sulinwithin5daysafterthediagnosis.All
subjects with available serum testing pos-
itive for GADAs and/or IA-2As on at least
one of the occasions were also analyzed
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veloped diabetes over the observation
period were analyzed for all four autoan-
tibodies in the samples taken in 1980 and
1986, if available. Sera were stored at
20°C until analyzed.
GADAs and IA-2As were quantiﬁed
with speciﬁc radioligand assays based on
the same principle as described in detail
elsewhere (9). The results were expressed
in relative units (RU), and these were
transformedintoWorldHealthOrganiza-
tion (WHO) units based on the WHO
standard serum. The cutoff limit for anti-
body positivity was set at the 99th
percentile in a separate series of 370
nondiabetic children and adolescents be-
ing 14.13 WHO units (5.36 RU) for
GADAs and 1.91 WHO units (0.43 RU)
for IA-2As. The disease sensitivity of the
GADA assay was 82% and the speciﬁcity
96% and the corresponding characteris-
ticsoftheIA-2Aassay72and100%inthe
2005 Centers for Disease Control and
Prevention–sponsored Diabetes Autoan-
tibody Standardization Program Work-
shop. Samples with GADAs or IA-2As
levels between the 97th and 99.5th per-
centiles were reanalyzed to conﬁrm the
antibodystatus.The1980and1986sam-
ples from the subjects seroconverting to
antibody positivity or negativity were re-
analyzed blindly in the same assay to ver-
ify the seroconversion.
ICAswereanalyzedbyastandardim-
munoﬂuorescence method from sections
of a frozen human group O pancreas as
described (9). The threshold for ICA de-
tectionwas2.5JuvenileDiabetesFounda-
tion (JDF) units.
IAA levels were measured with a mi-
croassay as described (9). A subject was
considered positive for IAAs when the
speciﬁc binding exceeded 1.55 RU (99th
percentile in 371 nondiabetic Finnish
subjects). The disease sensitivity of our
microassay was 58% and the speciﬁcity
98% in the 2005 Diabetes Autoantibody
Standardization Program Workshop.
Statistical analysis
The statistical evaluation was performed
using the 
2 test when analyzing differ-
ences in the frequencies of antibodies and
type 1 diabetes between groups unless
any expected value was less than ﬁve,
when Fisher exact test was applied. The
Mann-Whitney U test was used for com-
parisons between the levels of autoanti-
bodies. The Kaplan-Meier method was
used to construct life tables of the likeli-
hood of developing type 1 diabetes. The
log-rank test was used for comparison of
the survival distributions. Hazard ratios
(HRs)forfactorspotentiallypredictivefor
type 1 diabetes (sex, age at initial screen-
ing, initial GADA and IA-2A positivity, as
well as GADA and IA-2A levels) were as-
sessed with the Cox regression model. A
two-tailed P value of 0.05 was considered
Figure 1—A: Probability of remaining nondiabetic in Finnish subjects initially positive (n  34,
9 developed type 1 diabetes) or negative for GADAs (n  3,441, 9 developed type 1 diabetes); B:
positive(n22,9developedtype1diabetes)ornegative(n3453,9developedtype1diabetes)
for IA-2As; C: positive for GADAs and/or IA-2As (n  49; 11 developed type 1 diabetes) or
negativeforbothautoantibodies(n3426,7developedtype1diabetes);andD:inthoseinitially
positive for two (n  7, all developed type 1 diabetes), one (n  42, 4 developed diabetes), or no
(n  3,426, 7 developed type 1 diabetes) antibodies.
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and speciﬁcity as well as positive (PPV)
and negative (NPV) predictive values and
likelihood ratios (LR and LR) were
determined for the autoantibody
markers.
RESULTS— Fifteen boys and 19 girls
(0.9 vs. 1.1%; P  0.54) tested positive
for GADAs in the samples taken in 1980.
There was no difference in GADA titers
between sexes. Thirteen boys and nine
girls (0.8 vs. 0.5%; P  0.36) had IA-2As
in their initial sample, the boys having
higher titers than the girls (median 5.61
vs. 2.47 WHO units; P  0.05).
Among those with samples available
from 1986, 9 of 2,357 subjects negative
for GADAs in 1980 (0.4%) had serocon-
verted to GADA positivity. The positive
seroconversion rate did not differ signiﬁ-
cantly between male and female subjects
(0.5 vs. 0.2%, respectively). Six of 18 ini-
tially GADA-positive subjects (33%) had
experienced an inverse seroconversion.
Inverse seroconversions tended to be
morecommonamongfemalethanamong
male subjects (5 of 10 vs. 1 of 8; P 
0.09).SeroconversiontopositivityforIA-
2As was seen in 4 of 2,361 (0.2%) sub-
jects (boys 0.3%, girls 0.1%) over the
6-year period. The inverse seroconver-
sion rate was somewhat higher for IA-2As
(8 of 14; 57%) than that for GADAs, but
there was no sex difference. Individual
autoantibodydatainthesubjectswhoex-
perienced positive seroconversions and
corresponding data in subjects with in-
verse seroconversions are presented in
Table 1. One boy who tested positive for
IAAs only in 1980, but had GADAs and
ICAs in addition to IAAs in 1986, pre-
sented with overt diabetes in 1996.
Among six participants who experienced
an inverse seroconversion for GADAs by
1986, two progressed subsequently to
type 1 diabetes. One female progressor
had all four autoantibodies in 1980,
testedstillpositiveforIA-2AsandICAsin
1986, and presented with diabetes in
1988. The other progressor was a boy
who tested positive for GADAs only in
1980 and negative for all four autoanti-
bodies in 1986. He was diagnosed with
diabetes in 1992.
Over the observation period of 27
years 12 male and 6 female subjects de-
veloped clinical type 1 diabetes (0.7 vs.
0.3%; P  0.16). The progressors were
initially1.7yearsyoungerthanthenon-
progressors (aged 9.1 years [range 2.9–
18.9] vs. aged 10.8 years [2.7–18.9]; P 
0.14). The diabetes-free survival over
time is presented in relation to initial au-
toantibody status in Fig. 1. Both GADA
and IA-2A positivity were associated with
relativelyhighprobability(9of3426%
and9of2241%,respectively)oftype1
diabetes (Table 2). Similarly positivity for
GADAs and/or IA-2As was related to an
increased likelihood of progression to
overtdiabetes(Fig.1C).Allsevendouble-
positiveindividualsdevelopedclinicaldi-
abetes during the follow-up (Fig. 1D).
The GADA titers were of the same magni-
tude in the progressors and nonprogres-
sors positive for GADAs. The antibody-
positive progressors had higher titers of
IA-2As than the nonprogressors both
among male subjects (median 141.8 vs.
3.84 WHO units; P  0.005) and female
subjects (median 95.3 vs. 2.20 WHO
Figure 1—Continued.
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(11 of 18; 61%) who later presented with
type 1 diabetes tested positive for GADAs
and/or IA-2As, whereas the proportion
was1.1%(38of3,438)amongthenon-
progressors. Close to 40% of the progres-
sors tested initially positive for both
GADAs and IA-2As, while none of the
3,457 nonprogressors had both antibod-
ies in 1980. Individual autoantibody data
in the progressors are presented in Table
2. The predictive characteristics of
GADAs and IA-2As and their combina-
tions are shown in Table 3. Five progres-
sors (28%) tested negative for all four
autoantibodies in 1980. The autoanti-
body-positive progressors tended to be
older at diagnosis (mean age 20.2 years
[range 10.7–32.8]) than the antibody-
negative subjects (mean age 12.5 years
[5.5–20.3]; P  0.06). One of the pro-
gressors (case 7) tested positive for ICAs
only, the observed positivity preceding
clinical disease by 13.1 years.
In the Cox regression analysis, GADA
positivity (HR 37.4 [95% CI 11.0–
126.9]), IA-2A positivity (30.7 [6.9–
136.8]), and IA-2A level (1.02 [1.00–
1.04])wereassociatedwithincreasedrisk
for type 1 diabetes. Male sex was associ-
ated with a borderline increased HR (3.0
[0.98–9.2]), while age at initial screening
was not related to enhanced disease risk.
CONCLUSIONS — As soon the ﬁrst
effective preventive modality becomes
available for clinical use, there will be an
apparent need to extensively identify in-
dividuals at risk for progression to type 1
diabetes from the general population,
since the overwhelming majority of the
cases with newly diagnosed disease are
sporadic (12). The present data show that
one-time screening for GADAs and
IA-2As is capable of identifying 60% of
those individuals who will develop type 1
diabetes over the subsequent 27 years.
The highest PPV was seen in those testing
initially positive for both GADAs and
IA-2As, but the sensitivity dropped from
50% for either test alone to 39%.
The ﬁrst studies focusing on predic-
tion of type 1 diabetes in the general pop-
ulationusedICAsasamarker.Bruininget
al. (13) reported that the PPV of ICA pos-
itivity was 50% for type 1 diabetes when
observing 4,806 schoolchildren for 10
years, while Schatz et al. (14) observed a
PPVof18%associatedwithICApositivity
in 9,696 school children followed for a
maximum period of 8 years. The Wash-
ington State Diabetes Prediction Study
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1210 DIABETES CARE, VOLUME 33, NUMBER 6, JUNE 2010 care.diabetesjournals.orgshowed that positivity for at least two au-
toantibodies out of IAAs, GADAs, and
IA-2As was associated with a high sensi-
tivity(100%[95%CI58–100])andarea-
sonable positive predictive value (50%
[95% CI 25–75]) in initially 12- to 18-
year-old school children over a median
time period of 8 years (15). In the Swed-
ish ABIS Study, combined positivity for
GADAs and IA-2As at the age of 2.5 years
wasassociatedwithaPPVof11%forclin-
icaldiabetesbytheageof8years(16).All
the above-referenced studies have been
basedonalimitednumberofprogressors,
and the maximal follow-up time has been
10 years, whereas the present survey is
based on the longest observation period
ever reported (i.e., 27 years). Unfortu-
nately, no HLA data were available on the
participants in our study, which is an ap-
parent limitation. The current survey did
not set out to assess whether GADAs and
IA-2As are superior to other autoantibod-
ies, since ICAs and IAAs were analyzed
onlyinthosechildrenwhotestedpositive
for GADAs and/or IA-2As and/or devel-
oped clinical type 1 diabetes.
Our observation that both positive
and inverse seroconversions occurred
during an observation period of 6 years
conﬁrms that -cell autoimmunity repre-
sents a dynamic process as previously
shown in a Finnish family study (17).
Some studies (18,19) have claimed that
most positive seroconversions take place
beforetheageof6years.Thepresentdata
donotsupportsuchaphenomenon.One-
third of the subjects initially positive for
GADAstestednegativeforGADAs6years
later, whereas the proportion of inverse
seroconverters was close to 60% for IA-
2As. A majority of those (12 of 14) who
experienced an inverse seroconversion
tested positive for one single antibody in
their initial sample. The remaining two
still tested positive for at least one anti-
body in the subsequent sample. One of
the two children presented with clinical
diabetes in 1988. The inverse serocon-
verters initially positive for a single anti-
body all had relatively low antibody titers
intheirﬁrstsample.Takentogether,these
observations suggest that -cell autoim-
munitymaybeinducedatanyage,atleast
before the age of 20 years. Positivity for a
single autoantibody seems to reﬂect tran-
sient-cellautoimmunityinabouthalfof
such individuals. Regression to autoanti-
body negativity was not observed in any
of the seven subjects initially positive for
both GADAs and IA-2As, suggesting that
positivity for at least two diabetes-
associated autoantibodies represents, in
most cases, a point of no return.
Altogether 18 subjects (0.52% [95%
CI0.31–0.82])developedtype1diabetes
over the observation period of 27 years,
while the expected number of cases
would be 20 based on the recorded inci-
dence rate in the age-group from 3 to 35
years in Finland. Available data suggest
that the natural history of preclinical type
1 diabetes varies considerably from one
individual to another (20). In the present
series, the interval from the ﬁrst auto-
antibody-positive sample to clinical pre-
sentation of type 1 diabetes ranged from
0.9 to 20.3 years with a median of 8.6
years. When considering those 11 pro-
gressors who tested positive for at least
one diabetes-associated autoantibody in
the pre-diabetic period, the median inter-
val from the ﬁrst antibody-positive sam-
ple to the diagnosis of diabetes was 8.9
years with a minimum of 1 year and a
maximum of 20 years. Although we do
notknowtheexactageatseroconversion,
the observed range in the duration of the
pre-diabeticperiodsupportstheviewthat
there is substantial individual variation in
the progression rate to clinical diabetes.
Family studies have indicated that young
age at the appearance of the ﬁrst autoan-
tibodies, high antibody titers except for
GADAs (5), a high-risk HLA genotype,
and a reduced ﬁrst-phase insulin re-
sponse to intravenous glucose are all fac-
tors associated with an accelerated
progression to overt type 1 diabetes
(21,22). The Cox regression analysis re-
vealed expected predictors of type 1 dia-
betes, except that age at initial screening
turned out to be unrelated to diabetes
risk. This may be due to a longer obser-
vation time in the current study than in
previous reports, as seroconversion at
young age has been shown to be associ-
atedwithrapidprogressiontoclinicaldis-
ease (23), which may be neutralized by
longer follow-up.
Thereweresevenindividualswhode-
veloped diabetes with no detectable
GADAs or IA-2As in their initial sample.
Two individuals had positive IAAs or
ICAs. In the remaining ﬁve subjects, no
markers of humoral -cell autoimmunity
were detected in their pre-diabetic pe-
riod. There might be a series of alterna-
tive explanations to this observation.
Somepre-diabeticindividualsmayhave
seroconverted to autoantibody positivity
after the last sample available for testing,
whereas a few other may have tested pos-
itive for one or more autoantibodies ear-
lier, since there are examples of inverse
seroconversions in the pre-diabetic pe-
riod in some progressors (24). A conspic-
uous feature in the present series of
progressors is the overrepresentation of
male subjects (67%). This is, however,
consistent with the male predominance
among patients with type 1 diabetes diag-
nosed after puberty (25), as 61% of our
cases were diagnosed after the age of 15
years and all but two of these were male
subjects.
Thisstudydemonstratesthatitispos-
sible to identify individuals at high risk
Table 3— Sensitivity, speciﬁcity, positive predictive value (PPV), negative predictive value
(NPV), and positive and negative likelihood ratios (LR and LR) of GADAs and IA-2As for
type 1 diabetes over an observation period of 27 years
Autoantibody Sensitivity (%) Speciﬁcity (%) PPV (%) NPV (%) LR (%) LR (%)
GADA
Boys 42 99 33 99 71 0.6
Girls 67 99 21 99 78 0.3
All 50 99 26 99 69 0.5
IA-2A
Boys 42 100 38 100 89 0.6
Girls 67 100 44 100 234 0.3
All 50 100 41 100 133 0.5
GADA and/or IA-2A
Boys 58 99 28 99 55 0.4
Girls 67 99 17 99 59 0.3
All 61 99 22 99 56 0.4
GADA and IA-2A
Boys 39 100 100 100 424 0.3
Girls 67 100 100 100 1,170 0.7
All 39 100 100 100 1,346 0.4
Knip and Associates
care.diabetesjournals.org DIABETES CARE, VOLUME 33, NUMBER 6, JUNE 2010 1211for type 1 diabetes from the general pop-
ulation by screening for GADAs and IA-
2As. One subject tested positive for four
autoantibodies at the age of 11.9 years
and presented with clinical diabetes 20
years later, representing, as far as we
know, the longest preclinical period so far
observed. The occurrence of both positive
andinverseseroconversionsuptotheageof
24 years implies that -cell autoimmunity
represents a dynamic process, and that it
can be induced at any age in childhood and
adolescence and may be transient in a sub-
stantial proportion of subjects testing posi-
tive for a single antibody.
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